|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Tenecteplase#Adverse Reactions]] |
| {{Tenecteplase}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
|
| |
|
| ==Adverse Reactions==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| ===Bleeding===
| |
| The most frequent adverse reaction associated with TNKase is bleeding (see WARNINGS).
| |
| | |
| Should serious bleeding occur, concomitant heparin and antiplatelet therapy should be discontinued. Death or permanent disability can occur in patients who experience stroke or serious bleeding episodes.
| |
| | |
| For TNKase-treated patients in ASSENT-2, the incidence of intracranial hemorrhage was 0.9% and any stroke was 1.8%. The incidence of all strokes, including intracranial bleeding, increases with increasing age (see PRECAUTIONS: Geriatric Use).
| |
| | |
| In the ASSENT-2 study, the following bleeding events were reported (see Table 3).
| |
| | |
| {|
| |
| |-
| |
| |[[File:Tenecteplase04.jpg|thumb|800px]]
| |
| |-
| |
| |}
| |
| | |
| Non-intracranial major bleeding and the need for blood transfusions were lower in patients treated with TNKase.
| |
| | |
| Types of major bleeding reported in 1% or more of the patients were [[hematoma]] (1.7%) and gastrointestinal tract (1%). Types of major bleeding reported in less than 1% of the patients were urinary tract, puncture site (including cardiac catheterization site), [[retroperitoneal]], respiratory tract, and unspecified. Types of minor bleeding reported in 1% or more of the patients were [[hematoma]] (12.3%), urinary tract (3.7%), puncture site (including cardiac catheterization site) (3.6%), pharyngeal (3.1%), gastrointestinal tract (1.9%), epistaxis (1.5%), and unspecified (1.3%).
| |
| | |
| ===Allergic Reactions===
| |
| | |
| Allergic-type reactions (e.g., anaphylaxis, angioedema, laryngeal edema, rash, and urticaria) have rarely (< 1%) been reported in patients treated with TNKase. Anaphylaxis was reported in < 0.1% of patients treated with TNKase; however, causality was not established. When such reactions occur, they usually respond to conventional therapy.
| |
| | |
| ===Other Adverse Reactions===
| |
| | |
| The following adverse reactions have been reported among patients receiving TNKase in clinical trials. These reactions are frequent sequelae of the underlying disease, and the effect of TNKase on the incidence of these events is unknown.
| |
| | |
| These events include cardiogenic shock, [[arrhythmias]], [[atrioventricular block]], [[pulmonary edema]], heart failure, [[cardiac arrest]], recurrent [[myocardial ischemia]], myocardial reinfarction, myocardial rupture, [[cardiac tamponade]], [[pericarditis]], [[pericardial effusion]], [[mitral regurgitation]], [[thrombosis]], [[embolism]], and [[electromechanical dissociation]]. These events can be life-threatening and may lead to death. [[Nausea]] and/or [[vomiting]],[[hypotension]], and fever have also been reported.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TNKASE (TENECTEPLASE) KIT [GENENTECH, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69e391bf-1250-4083-aa60-6aa41c33657f | publisher = | date = | accessdate = 6 February 2014 }}</ref>
| |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Thrombolytic drugs]]
| |
| [[Category:Cardiovascular Drugs]] | |
| [[Category:Drugs]] | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |